Company intelligence / Profile preview

Curie.Bio

Boston, Massachusetts, United Statescurie.bio ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Curie.Bio is not a drug developer itself but has invested in 26+ early-stage biotech startups since 2022. Its model combines seed investment with hands-on support from a team of experienced drug developers to help founders advance therapeutics from concept through meaningful clinical milestones. The company’s approach aims to increase the success rate for new medicines while minimizing founder dilution.

Therapeutic areas: ImmunologyRare Diseases
Modalities: small moleculesoligonucleotide therapeutics
Industry: Investors

Partnerships

Secarna Pharmaceuticals

Beyond the preview

Go deeper on Curie.Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curie.Bio.

Explore the full profile